Chemotherapy dose intensity response median survival median progression-free survival metastatic neuroblastoma efficacy commonly drugs teniposide cisplatin CDDP cyclophosphamide CPM DOXO vincristine VCR retrospective analysis clinical trials induction chemotherapy stage IV neuroblastoma patients year age Dose intensity DI drug milligrams square meter week Linear regression analyses Dls CDDP influence clinical outcomes ie proportion major response median survival median progression-free survival PFS CPM DOXO significant VCR influence clinical end points many protocols treatment year none end points duration therapy Twenty-one weeks adequate superior response median survival median PFS results maximal dose intensification selective drugs short duration outcome patients poor-risk neuroblastoma 